Rosuvastatin in Combination With Bortezomib Promotes Osteogenesis in Myeloma Bone Disease by Inhibiting the Secretion of CCL3

Puntos clave

Enhanced osteogenesis occurs due to the combined effect of rosuvastatin and bortezomib, which inhibits CCL3.
The study shows significant inhibition of CCL3, contributing to effective bone remodeling in myeloma bone disease.
Assessment using the synergistic effects of rosuvastatin and bortezomib reflects promising outcomes in bone health.
This strategy suggests a potential therapeutic avenue, needing further validation in myeloma bone disease models.

Resumen

The combination of rosuvastatin and bortezomib exerts a synergistic effect by inhibiting CCL3, thereby rebalancing bone remodeling and promoting osteogenesis. This strategy represents a promising novel therapeutic approach for mitigating MBD.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

FuJun QU

Mingxu Hui

Guilin Medical University

Fan Yang

Guilin Medical University

Journals

SHILAP Revista de lepidopterología

eJHaem

Actions

Institutions

Guilin Medical University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

QU et al. (Wed,) studied this question.

synapsesocial.com/papers/69a75be3c6e9836116a2402f — DOI: https://doi.org/10.1002/jha2.70232

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma· 2000 · 78 citations
Bortezomib inhibits human osteoclastogenesis· 2007 · 205 citations
Pathogenesis of myeloma bone disease· 2008 · 401 citations
PDLIM7 Promotes Tumor Metastasis in Papillary Thyroid Carcinoma via Stabilizing Focal Adhesion Kinase Protein· 2024 · 8 citations
The pharmacology of statins· 2014 · 698 citations

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma· 2000 · 78 citations
Bortezomib inhibits human osteoclastogenesis· 2007 · 205 citations
Pathogenesis of myeloma bone disease· 2008 · 401 citations
PDLIM7 Promotes Tumor Metastasis in Papillary Thyroid Carcinoma via Stabilizing Focal Adhesion Kinase Protein· 2024 · 8 citations
The pharmacology of statins· 2014 · 698 citations

Rosuvastatin in Combination With Bortezomib Promotes Osteogenesis in Myeloma Bone Disease by Inhibiting the Secretion of CCL3

Puntos clave

Resumen

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider